Emergence and Spread of *Neisseria gonorrhoeae* Strains with High-level Resistance to Azithromycin in Taiwan from 2001 to 2018

Yen-Hung Liu\(^{a,b}\), Ya-Hui Wang\(^{c,d}\), Chun-Hsing Liao\(^{e,f}\), Po-Ren Hsueh\(^{g,h}\)

\(^a\)Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

\(^b\)Department of Internal Medicine, Cardinal Tien Hospital, Taipei, Taiwan

\(^c\)Medical Research Center, Cardinal Tien Hospital and School of Medicine, Taipei, Taiwan

\(^d\)College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

\(^e\)Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei County, Taiwan

\(^f\)Department of Medicine, Yang-Ming University, Taipei, Taiwan

\(^g\)Department of Laboratory Medicine, National Taiwan; University Hospital,

College of Medicine, National Taiwan University, Taipei, Taiwan

\(^h\)Department of Internal Medicine, National Taiwan University Hospital,
College of Medicine, National Taiwan University, Taipei, Taiwan

Address correspondence to Po-Ren Hsueh,

hsporen@ntu.edu.tw

Running title: High-level azithromycin resistance in *N. gonorrhoeae*
ABSTRACT A total of 598 Neisseria gonorrhoeae isolates obtained from patients in Taiwan from 2001 to 2018 were evaluated. The minimum inhibitory concentrations (MICs) of ceftriaxone (CRO) and azithromycin (AZM) against the isolates were determined by the agar dilution method. N. gonorrhoeae isolates with AZM MICs of ≥ 1 μg/ml were identified and characterized by the presence of AZM resistance determinants. For high-level AZM-resistant isolates (AZM-HLR, MIC ≥ 256 μg/ml), genotyping was performed using multilocus sequence typing (MLST) and N. gonorrhoeae multi-antigen sequence typing (NG-MAST). Among the N. gonorrhoeae isolates studied, 8.7% (52/598) exhibited AZM MICs of ≥ 1 μg/ml. Thirteen of the 52 isolates contained A2059G (23S rRNA NG-STAR type1) or C2611T (23S rRNA NG-STAR type 2) mutations. The prevalence of A2059G mutation was higher in AZM-HLR isolates (p < 0.001). The -35A deletion in the promoter region of the mtrR gene did not differ between AZM-HLR isolates (100%, 10/10) and the isolates with AZM MICs of 1 μg/ml to 64 μg/ml (95.2%, 40/42) (p = 1.000). The presence of mutations in the mtrR coding region was significantly different between these two groups, 90% (9/10) and 26.2% (11/42), respectively (p < 
The AZM-HLR isolates, all carrying four mutated A2059G alleles, a -35A deletion, and G45D, were classified as MLST 12039/10899 and NG-MAST 1866/16497. In conclusion, Taiwan is among the countries reporting gonococci with high level resistance to AZM so that single dose of ceftriaxone 1g intramuscularly as the first choice for management of *N. gonorrhoeae* infection should be evaluated.
Sexually transmitted disease caused by *Neisseria gonorrhoeae* (*N. gonorrhoeae*) is a global problem, and in 2012, the World Health Organization (WHO) estimated that the number of new cases of gonococcal infection worldwide was 78.3 million (1). In Taiwan, the incidence of *N. gonorrhoeae* infection has increased continuously, from 6.7 cases per 100,000 people in 2005 to 19.5 cases per 100,000 people in 2017 (2).

A wide spectrum of clinical manifestations and complications of *N. gonorrhoeae* infection has been observed, and no vaccine against *N. gonorrhoeae* is available at present; therefore, infection control predominantly relies on timely diagnostics with appropriate antibiotic therapy (1, 3, 4). Over time, the rapid development of *N. gonorrhoeae* resistance to a broad range of antimicrobial agents worldwide has threatened the management of *N. gonorrhoeae* infection (1). As the waning susceptibility of *N. gonorrhoeae* and the emergence of treatment failure with cephalosporins have been documented in several countries in 2000s, dual therapy with ceftriaxone (CRO) (250 mg or 500 mg administered intramuscularly) plus azithromycin (AZM) (1 g or 2 g given orally) has been widely accepted as the first choice for the
65 treatment of gonorrhea to ensure effective treatment and limit the development
66 of antimicrobial resistance (3).
67
68 AZM exercises its capability to inhibit protein synthesis of *N. gonorrhoeae*
69 by binding to the 23S rRNA component of the 50S ribosomal subunit. Specific
70 mutations of 23S rRNA, i.e., A2059G and C2611T (*Escherichia coli*
71 numbering), have been demonstrated to be associated with AZM resistance in
72 *N. gonorrhoeae* (3). Mutations either in the coding region of the *mtrR* gene or
73 in the *mtrR* promoter, leading to overexpression of the MtrCDE efflux pump,
74 also affect AZM susceptibility (3). Other unusual mutations in *N. gonorrhoeae,*
75 such as mutations in the genes *erm, mef,* *rplD,* and *rplV,* also conferred AZM
76 resistance (3, 5).
77
78 In Taiwan, the rate of AZM resistance in *N. gonorrhoeae* isolates collected
79 in northern Taiwan from 2001 to 2013 was demonstrated to be 1.3% based on
80 the current minimum inhibitory concentrations (MICs) interpretive criteria
81 recommended by the Clinical and Laboratory Standards Institute (CLSI), while
82 the rate of non-wild type was demonstrated to be 14.6% using the current MIC
83 interpretive criteria recommended by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) (6). Because of the emergence of *N. gonorrhoeae* isolates with resistance to both CRO and AZM globally (7, 8), the continuous monitoring of resistance to AZM and the comprehension of relevant molecular mechanisms at a national level is crucial, particularly for regions with the presence of isolates exhibiting high-level resistance to AZM (AZM-HLR, MICs of $\geq 256 \mu g/ml$).

In the present study, we investigated nationwide trends of resistance to AZM and the related molecular mechanisms of *N. gonorrhoeae* isolates in Taiwan from 2001 to 2018.
RESULTS

**Antimicrobial susceptibilities of the isolates.** The MIC distributions of CRO and AZM for the 598 *N. gonorrhoeae* isolates are demonstrated in Figure 1. The MICs of CRO ranged from 0.015 μg/ml to 0.25 μg/ml, with an MIC<sub>50</sub> of 0.03 μg/ml and MIC<sub>90</sub> of 0.12 μg/ml. Only three isolates (0.5%) exhibited resistance to CRO (MICs > 0.125 μg/ml). The MICs of AZM ranged from 0.03 μg/ml to ≥ 256 μg/ml, with an MIC<sub>50</sub> and MIC<sub>90</sub> of 0.25 μg/ml and 0.5 μg/ml, respectively. Fifty-two isolates (8.7%) exhibited AZM MICs of ≥ 1 μg/ml.

Among the 598 isolates, 13 (2.2%) were AZM NWT isolates (MICs of ≥ 2 μg/ml). Of the 13 AZM NWT isolates, two (0.3%) exhibited MIC of 2 μg/ml, one (0.17%) had MIC of 16 μg/ml and 10 (1.7%) had MICs of ≥ 256 μg/ml (AZM-HLR). No isolates exhibiting resistance to CRO and NWT to AZM were noted.

**Azithromycin resistance determinants and penA allele.** Among the 52 isolates with AZM MICs of ≥ 1 μg/ml, 13 (25%) contained A2059G (23S rRNA NG-STAR type1) or C2611T (23S rRNA NG-STAR type 2) mutated alleles in domain V of 23S rRNA (Table 1). Ten of those isolates possessed A2059G
substitution in all four alleles of 23S rRNA, demonstrating high level resistance to AZM with MIC of ≥ 256 μg/ml, and one isolate had a single mutated A2059G allele with MIC of 1 μg/ml. The prevalence of A2059G mutation was higher in AZM-HLR isolates (p < 0.001). In the other two isolates, a C2611T substitution in 1 or 4 alleles of 23S rRNA were detected with an MIC of 1 μg/ml and 2 μg/ml, respectively.

Fifty (96.1%, 50/52) isolates bore a -35A deletion in the 13-bp inverted-repeat sequence. Of the 42 isolates with AZM MICs of 1 μg/ml to 64 μg/ml, the majority (73.8%, 31/42) were wild type for the mtrR coding region, 19.0% (8/42) had A39T, and 7.14% (3/42) had G45D. Of the 10 AZM-HLR isolates, no A39T was identified, while 10% (1/10) were wild type for the mtrR coding region, and 90.0% (9/10) had G45D. Analysis of the mtrR promoter region revealed that the prevalence of the -35A deletion was no different in AZM-HLR isolates (100%, 10/10) from that in the isolates with AZM MICs of 1 μg/ml to 64 μg/ml (95.2%, 40/42) (p =1.000) (Table 1). In contrast, the presence of mutation in the mtrR coding region was significantly different between these two groups (p < 0.001) (Table 1).
All of the 10 AZM-HLR isolates carried the non-mosaic penA allele, including nine isolates of NG-STAR type 106 and one of NG-STAR type 2 (Figure 2).

Genetic relatedness of *N. gonorrhoeae* isolates with AZM MICs of ≥ 1 μg/ml. The 52 *N. gonorrhoeae* isolates with AZM MICs of ≥ 1 μg/ml comprised 24 different MLST types. Thirteen (54.2%, 13/24) sequence types (STs) were represented by only a single isolate, and the remaining STs were represented by two or more isolates. The most prevalent STs among the 42 isolates of AZM MIC 1 μg/ml to 64 μg/ml were ST1901 (21.4%, n=9), ST1583 (7.1%, n=3), ST7371 (7.1%, n=3), and ST11196 (7.1%, n=3). Among the 10 AZM-HLR isolates, nine isolates (90%) were identified as MLST12039 and one (10%) belonged to MLST10899. NG-MAST analysis of the 10 AZM-HLR isolates revealed two types: NG-MAST1866 (60%, n=6) and NG-MAST16497 (40%, n=4) (Figure 2).

PFGE and phylogenetic analysis of AZM-HLR isolates. PFGE analysis of the 10 AZM-HLR isolates revealed 12 ± 2 bands (Figure 2). Cluster analysis of the resulting dendrograms defined four clusters (Cluster A to D) at the level
Cluster A encompassed six isolates, collected from northern and eastern Taiwan, and all were determined to be MLST12039 but belonged to two different NG-MASTs (1866 and 16497). In contrast, the two isolates in Cluster B belonged to the same NG-MAST 1866 but were defined as MLST12039 and 10899, respectively. Cluster C consisted of only one isolate, typed as MLST12039 and NG-MAST1866. Lastly, Cluster D contained one isolate designated as MLST12039 and NG-MAST16497 (Figure 2).

Clinical characteristics of the 10 patients infected with AZM-HLR isolates. The 10 patients (9 males and 1 female) with a median age of 37 years (range 21-83 years) had gonococcal urethritis caused by AZM-HLR isolates. Nine of them were diagnosed during the 2017-2018 period and one was infected in 2013 (Figure 2). Geographical spread was throughout Taiwan: six from northern Taiwan, three from eastern Taiwan, and one from central Taiwan. No sexual contact between each of them was reported. All of them were negative for HIV and syphilis infection. None of them had macrolide exposure within 60 days of diagnosis of *N. gonorrhoeae* infection, nor recent international travel history, except one patient who lived in Shenzhen, China.
DISCUSSION

In 2019, EUCAST recommended epidemiologic cutoff values (ECOFF) of 1 µg/ml for AZM among *N. gonorrhoeae* isolates to segregate bacterial populations into those belonging to WT and those with acquired and/or mutational resistance mechanisms (NWT), so that *N. gonorrhoeae* isolates of AZM MIC ≤ 1 µg/ml were classified as WT (9). In 2019, CLSI recommended clinical breakpoints of AZM and defined isolates with AZM MICs of ≤ 1 µg/ml as susceptible (10). However, many studies, including our present study, showed *N. gonorrhoeae* strains with AZM MIC of 1 µg/ml carried C2611T mutated 23S rRNA allele or mtrR gene (5, 11-13). It is noteworthy that AZM resistance determinants were also recognized in *N. gonorrhoeae* isolates of AZM MIC < 1 µg/ml (11, 12, 14). Close monitoring and further research is needed to monitor the evolution of the wild type *N. gonorrhoeae*.

Emergence of AZM-HLR *N. gonorrhoeae* has been described in many countries, including Argentina in 2009 (15), the United States in 2012 (16), Australia in 2015 (17), Canada in 2016 (11), China in 2016 (18), and the U.K. in 2018 (12). In this study, we first report the emergence and clustering of
AZM-HLR *N. gonorrhoeae* in Taiwan. During the study period, 10 AZM-HLR isolates were gathered from different patients: one in 2013, four in 2017 and five in 2018. None of these patients had been treated with macrolide within 60 days of diagnosis of *N. gonorrhoeae* infection, compatible with the earlier study that no association between previous azithromycin exposure and subsequent azithromycin-resistant *N. gonorrhoeae* isolates. (19) Although this finding cannot imply us of development of azithromycin resistance, either bystander or direct selection (20), analysis of molecular typing of these AZM-HLR isolates is necessary. These isolates were sequenced as MSLT12039/10899 and NG-MAST 1866/16497, respectively. All of them had non-mosaic *penA* alleles and the same AZM resistance determinants, including 4 mutated 23S rRNA copies with A2059G mutation, -35A deletion in the promoter region of the *mtrR* gene, and G45D mutation in the *mtrR* coding region. The results of genotyping and PFGE suggest the clonal spread of AZM-HLR isolates in Taiwan and the circulation of a certain strain through sexual networks, instead of de novo development. Furthermore, through the implementation of MLST and NG-MAST genotyping, it could be inferred that
the AZM-HLR isolates circulating in Taiwan may originate from an internationally successful clone that evolved with spontaneous genetic events to the current variation observed in our study. China reported that AZM-HLR *N. gonorrhoeae* isolates belonging to NG-MAST1866 in Hangzhou city in 2011-2012 carried identical AZM resistance determinants to our isolates, including the A2059G mutation, -35A deletion, and G45D mutation (18). Furthermore, in early 2018, the U.K. and Australia reported CRO and AZM-resistant isolates G97687 and A2735, respectively, and they were typed as the same genotype, MLST12039 and NG-MAST16848 (7, 8). Compared to G97687 and A2735, our AZM-HLR isolates share the same MLST type, 12039, and almost identical NG-MAST profile, NG-MAST1866 and 16497, with a difference of 2-3 SNPs, implying that our AZM-HLR isolates and G97687/A2735 might be clonally related. The discrepancy between the typing results of MLST and NG-MAST may arise from different targeted DNA sequences. MLST identifies seven relatively conserved housekeeping genes (*abcZ, adk, aroE, fumC, gdh, pdhC*, and *pgm*) and is more suitable to deal with the macro-epidemiology, whereas NG-MAST associates with two variable
genes, porB and tbpB, which explains its potential for micro-epidemiological investigations and its greater discriminatory ability than MLST. However, due to horizontal transfer of porB alleles among N. gonorrhoeae isolates, it is difficult to precisely describe the phylogenetic relationship between N. gonorrhoeae isolates solely based on the method of NG-MAST. (21, 22)

Therefore, whole-genome sequencing (WGS) of globally reported AZM-HLR isolates to provide higher level of discrimination is needed to confirm international transmission.

Earlier study found one A2059G mutated 23S rRNA allele in AZM-susceptible isolates (MIC of 0.25 μg/ml) and also demonstrated that AZM-HLR isolates were descendants of the low-level resistant isolates (MIC of 1 μg/ml) and the susceptible isolates, supporting the theory that once a mutated allele exists within the organism, the further acquisition of multiple mutated alleles occurs without high barriers (12, 23). Owing to one isolate harboring a A2059G mutation in a single allele of 23S rRNA with AZM MIC of 1 μg/ml in our study, it is of concern that our isolates of AZM MIC < 1 μg/ml may carry the A2059G mutation, and endogenous homologous recombination can
be anticipated under the selection pressure, leading to a yield of AZM-HLR isolates (23). Moreover, as the frequency of chromosomal DNA transformation in gonococci can be very high ($10^{-2}$/μg DNA/$10^8$ CFU) (3), we should be concerned that our isolates were only one step away from horizontal transfer of mosaic penA allele to display resistance to both CRO and AZM. To keep the efficacy of CRO and AZM for the treatment of gonorrhea, substantially comprehensive surveillance of antimicrobial resistance and adequate prescription of AZM is necessary.

The contributions of mtrR mutations to AZM resistance has been controversial. Formerly, the hierarchy of mtrR locus mutation regarding the MtrCDE efflux pump system had been established; that is, the promoter mutation expressed high levels of resistance (by $\geq 10$-fold) while the missense mutations in the mtrR coding sequence typically resulted in a low- to mid- level of resistance (by 2- to 4-fold) (24). However, our results showed that only the mutation in the mtrR coding region, not the presence of -35A deletion, has impact on AZM MICs, a similar finding to Chuan’s study (25). In contrast, WGS analysis of AZM-resistant (MIC $> 2$ μg/ml) N. gonorrhoeae isolates (n = 75)
Europe from 2009 to 2014 revealed that neither mutations in mtrR nor its promoter significantly affect the MIC of AZM (26). Grad et al. further revealed that mtrR mutations were not associated with AZM resistance, and 81% of the collected isolates in the United States from 2000 to 2013 were resistant to AZM with unexplained mechanism (27). The complex may be partially explained by epistatic interactions at the mtrR gene obtained from multiple commensal Neisseria spp., such as Neisseria meningitidis and Neisseria lactamica, through DNA transformation (28).

This study had several potential limitations. First, not all of the collected isolates were tested to determine the presence of antimicrobial resistance determinants, causing the underestimation of the clinical impact of these determinants. Second, information on antibiotic exposure history was lacking, so selection pressure on the dynamics of N. gonorrhoeae strains cannot be clearly elucidated. Third, with the lack of comparison of WGS data, it is hard to sharply draw the links between our isolates and internationally reported AZM-resistant strains to take timely action to preserve the efficacy of AZM for N. gonorrhoeae infection.
In conclusion, we presented the clonal spread of AZM-HLR isolates in Taiwan through sexual networks, and these isolates may originate from internationally successful isolates. A2059G mutated 23S rRNA was encountered in our study, and therefore we should pay close attention to the possible emergence of *N. gonorrhoeae* isolates with resistance to both CRO and AZM through spontaneous mutation and DNA transformation. Taiwan is now on the list of countries reporting gonococci with high level resistance to AZM, compromising the efficacy of dual therapy with CRO plus AZM, so that we may follow the recommendation of British Association for Sexual Health and HIV and take single dose of ceftriaxone 1g intramuscularly as the first choice for management of *N. gonorrhoeae* infection. (29) Comprehensive efforts to avoid untreatable gonorrhea and reduce the burden of disease should be also taken across regional and national boundaries.
METHODS

Bacterial isolates. From January 2001 to September 2018, 598 N. gonorrhoeae isolates were recovered from various sources, including urethral discharge, vaginal secretion, skin pus, eye discharge, blood, surgical wound, gastric juice, synovial fluid, and Bartholin abscess, of 598 patients, mainly from a medical center in northern Taiwan (62.2%, 372/598). The remaining isolates were obtained from other eight medical centers/regional hospitals in different geographical areas of Taiwan: northern Taiwan, 17.6% (n=105); central Taiwan, 13.0% (n=78); southern Taiwan, 4.5% (n=27); and eastern Taiwan, 2.7% (n=16). These isolates were identified as oxidase-positive, gram-negative, and kidney-shaped diplococci with slightly concave adjacent surfaces in smears and were confirmed by Vitek 2 system (bioMérieux, Marcy l’Etoile, France). All isolates were stored in trypticase soy broth with 20% glycerol at −70°C. For further testing, these isolates were retrieved from storage, inoculated on chocolate agar, and incubated at 37°C in a 5% CO2-enriched atmosphere (6).
Collection of patient data. Patients with *N. gonorrhoeae* infection were identified through review of microbiology laboratory records at the participating hospitals in Taiwan. The medical records of patients with AZM-HLR *N. gonorrhoeae* infection were retrospectively reviewed, including history of human immunodeficiency virus (HIV) infection, syphilis, macrolide exposure within 60 days when *N. gonorrhoeae* infection was diagnosed, and travel history. The Institutional Review Board (IRB) of the National Taiwan University Hospital (201609066RINB) approved this study. Informed consent was waived by the IRB due to the retrospective nature of the project, and the study was performed in accordance with the Declaration of Helsinki.

Antimicrobial susceptibility testing. MICs of the isolates resistant to CRO and AZM were determined by the agar dilution method using GC agar (Difco GC medium base; BBL Microbiology Systems, Cockeysville, MD) with a 1% defined growth supplement (IsoVitaleX™; BBL Microbiology Systems, Becton and Dickinson, Sparks, MD, USA), as described previously (6). CRO and AZM were purchased from Sigma (Taipei, Taiwan). *N. gonorrhoeae* ATCC 49226 was used as the control strain.
N. gonorrhoeae isolates with AZM MICs of $\leq 1 \mu g/ml$ were defined as susceptible to AZM by the guidelines recommended by the CLSI (10). However, the EUCAST recommended an epidemiologic cutoff value (ECOFF) of $1 \mu g/ml$ for defining WT (MICs of $\leq 1 \mu g/ml$) and NWT (MICs of $>1 \mu g/ml$) to AZM (9). In this study, N. gonorrhoeae isolates with AZM MICs of $\geq 256 \mu g/ml$ were defined as AZM-HLR. The MIC breakpoints used to determine resistance to CRO (MIC $>0.125 \mu g/ml$) was in accordance with the 2019 EUCAST guideline (9).

**Antimicrobial resistance determinants.** To identify the presence of mutations, gene sequences of domain V of the 23S rRNA, the mtrR, and the penA genes were amplified by polymerase chain reaction (30, 31). The DNA sequencing data was uploaded to a publicly accessible database on the NG-STAR website (https://ngstar.canada.ca), hosted by the Public Health Agency of Canada, National Microbiology Laboratory, to determine the antimicrobial resistance markers, including numbers of alleles with mutated A2059G or C2611T, -35A deletion of mtrR promoter region, mtrR coding gene and penA type.
Multilocus sequence typing (MLST) and multi-antigen sequence typing (NG-MAST) for isolates with AZM MICs of $\geq 1 \mu g/ml$. Genetic relatedness of *N. gonorrhoeae* isolates with AZM MICs of $\geq 1 \mu g/ml$ was determined by using the MLST and NG-MAST methods as previously described (32, 33). In the *N. gonorrhoeae* MLST scheme, seven housekeeping genes, namely *abcZ*, *adk*, *aroE*, *fumC*, *gdh*, *pdhC*, and *pgm*, were amplified and sequenced. The sequences were submitted to the MLST website (https://pubmlst.org/neisseria/) to assign sequence types (STs). AZM-HLR *N. gonorrhoeae* isolates were additionally typed by NG-MAST method. NG-MAST allele numbers of *porB* and *tbpB* and STs were obtained through the NG-MAST website (http://www.ng-mast.net) (33).

**Pulsed-field gel electrophoresis (PFGE) for AZM-HLR isolates.** PFGE analysis was performed for AZM-HLR isolates only. DNA of the isolates was digested by the restriction enzyme *NheI*, and the restriction fragments were separated in a CHEF-DRIII unit (Bio-Rad Laboratories, Hercules, CA, USA) at 200 V for 27 hours. The pulsotypes were analyzed using the Bio-Rad CHEF-Mapper apparatus (Bio-Rad Laboratories, Hercules, CA). Cluster...
analysis was performed using BioNumerics version 5.0 (Applied Maths, Sint-Martens-Latem, Belgium) and the unweighted pair-group method with arithmetic averages (UPGMA). The Dice correlation coefficient was used with a tolerance of 1% in order to analyze any similarities between banding patterns. Isolates showing identical PFGE patterns were considered to be the same strain (same pulsotypes) and isolates exhibiting PFGE patterns with a similarity of >80% were considered to represent closely related strains.

Statistical analysis. Statistical significance was assessed using SPSS 13.0 (SPSS Inc, Chicago, IL). Fisher’s exact test was used for statistical analyses. A p-value < 0.001 was considered to be significant.
REFERENCES


https://doi.org/10.1016/S1473-3099(18)30122-1.


16.


Table 1  Comparison of antimicrobial resistance determinants in isolates of azithromycin MIC 1 μg/ml to 64 μg/ml versus high-level azithromycin-resistant isolates (MIC ≥ 256 μg/ml) Neisseria gonorrhoeae isolates

<table>
<thead>
<tr>
<th>Resistance determinants</th>
<th>No. (%) of N. gonorrhoeae isolates with indicated MICs (n=52)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MIC= 1-64 μg/ml (n=42)</td>
<td>MIC ≥ 256 μg/ml (n=10)</td>
</tr>
<tr>
<td>23S rRNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2059G</td>
<td></td>
<td></td>
</tr>
<tr>
<td>wild type</td>
<td>41 (97.6)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>A2059G in 1-2 alleles</td>
<td>1 (2.40)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>A2059G in 3-4 alleles</td>
<td>0 (0.00)</td>
<td>10 (100)</td>
</tr>
<tr>
<td>C2611T</td>
<td></td>
<td></td>
</tr>
<tr>
<td>wild type</td>
<td>40 (95.2)</td>
<td>10 (100)</td>
</tr>
<tr>
<td>C2611T in 1-2 alleles</td>
<td>1 (2.44)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>C2611T in 3-4 alleles</td>
<td>1 (2.44)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>mtrR promoter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>wild type</td>
<td>2 (4.88)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>-35A deletion</td>
<td>40 (95.2)</td>
<td>10 (100)</td>
</tr>
<tr>
<td>mtrR coding region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>wild type</td>
<td>31 (73.8)</td>
<td>1 (10.0)</td>
</tr>
<tr>
<td>A39T</td>
<td>8 (19.0)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>G45D</td>
<td>3 (7.14)</td>
<td>9 (90.0)</td>
</tr>
</tbody>
</table>
FIG 1 Distribution of the minimum inhibitory concentrations (MICs) for azithromycin (A) and ceftriaxone (B) against 598 isolates of Neisseria gonorrhoeae from January 2001 to September 2018.
FIG 2 Pulsed-field gel electrophoresis profiles using the restriction enzyme Nhel and a dendrogram of the 10 high-level azithromycin-resistant isolates.

With a cut-off at 80% of similarity, four major clusters (A, B, C, and D) were identified. The year and region of collection, minimal inhibitory concentrations of azithromycin and ceftriaxone are shown. Genetic relatedness determined by MLST and NG-MAST, and resistance determinants, including A2059G mutation, promoter region and coding region of mtrR gene, and penA, are indicated. AZM, azithromycin. CRO, ceftriaxone. MIC, minimum inhibitory concentration. MLST, multilocus sequence typing. NG-MAST, N. gonorrhoeae multi-antigen sequence typing. A-del, -35A deletion.
Figure 1

(A) Azithromycin

No. of isolates

MIC (μg/ml)

≤0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 ≥256

No. of isolates
Figure 1

(B) Ceftriaxone

No. of isolates

MIC (µg/ml)

0
0.015
0.03
0.06
0.12
0.25
1
2
3
50
100
150
200
250
300

≤0.015
0.03
0.06
0.12

131
142
67
<table>
<thead>
<tr>
<th>Year</th>
<th>Location, Taiwan</th>
<th>AZM, MIC (µg/ml)</th>
<th>CRO, MIC (µg/ml)</th>
<th>MLST</th>
<th>NG-MAST</th>
<th>16S rRNA type by NG-STAR (no. of typed alleles)</th>
<th>mtrR promoter coding</th>
<th>penA type by NG-STAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>Northern</td>
<td>&gt;256</td>
<td>0.015</td>
<td>12039</td>
<td>1866</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Northern</td>
<td>256</td>
<td>0.03</td>
<td>12039</td>
<td>1866</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Eastern</td>
<td>&gt;256</td>
<td>0.06</td>
<td>12039</td>
<td>1866</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>Eastern</td>
<td>&gt;256</td>
<td>0.015</td>
<td>12039</td>
<td>16497</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>Eastern</td>
<td>256</td>
<td>0.015</td>
<td>12039</td>
<td>16497</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>Eastern</td>
<td>256</td>
<td>0.015</td>
<td>12039</td>
<td>16497</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>Northern</td>
<td>256</td>
<td>0.015</td>
<td>12039</td>
<td>16497</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>Northern</td>
<td>256</td>
<td>0.015</td>
<td>12039</td>
<td>16497</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Northern</td>
<td>&gt;256</td>
<td>0.03</td>
<td>10899</td>
<td>1866</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Central</td>
<td>&gt;256</td>
<td>0.03</td>
<td>12039</td>
<td>1866</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>Northern</td>
<td>&gt;256</td>
<td>0.03</td>
<td>12039</td>
<td>16497</td>
<td>1 (4) A-del G45D</td>
<td>106</td>
<td></td>
</tr>
</tbody>
</table>

Figure 2

Identity (%)